Clinical Cancer Research, Vol 4, Issue 2 325-329, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy

Z Lu, R Zhang, JT Carpenter and RB Diasio
Department of Pharmacology and Toxicology, University of Alabama at Birmingham 35294, USA.

Dihydropyrimidine dehydrogenase (DPD) is the initial, rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents in the treatment of breast cancer. The objective of this study was to determine the population characteristics of DPD activity in patients with breast cancer as well as the frequency of DPD deficiency in this population. DPD activity in peripheral blood mononuclear cells (PBM-DPD) was determined in 360 patients with breast cancer, with the mean PBM-DPD (0.26 +/- 0.01 nmol/min/mg protein) being significantly lower than that observed in female controls (0.44 +/- 0.02 nmol/min/mg protein; P < 0.01). ANOVA analysis examining the significance of differences in DPD activity among various groups indicated that only disease difference (breast cancer versus normal subjects) was significant after adjustments for race and age. In the present study, 21 (5.8%) patients were considered to be DPD deficient, indicating that this pharmacogenetic syndrome may be more common than anticipated (no DPD-deficient individual was found in the controls). Significantly lower DPD activity in patients with breast cancer may predispose to 5-FU-associated toxicity. These results provide further rationale for individualizing the 5-FU dose, thus reducing the risk of toxicity and/or improving therapeutic efficacy in patients with breast cancer.

This article has been cited by other articles:

				L. K. Mattison, J. Fourie, R. A. Desmond, A. Modak, M. W. Saif, and R. B. Diasio Increased prevalence of dihydropyrimidine dehydrogenase deficiency in african-americans compared with Caucasians. Clin. Cancer Res., September 15, 2006; 12(18): 5491 - 5495. [Abstract] [Full Text] [PDF]

				K. R. Crews Individualizing chemotherapeutic treatment of colorectal cancer Am. J. Health Syst. Pharm., May 1, 2006; 63(9_Supplement_2): S12 - S17. [Abstract] [Full Text] [PDF]

				L. K. Mattison, J. Fourie, Y. Hirao, T. Koga, R. A. Desmond, J. R. King, T. Shimizu, and R. B. Diasio The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil Clin. Cancer Res., January 15, 2006; 12(2): 549 - 555. [Abstract] [Full Text] [PDF]

				T. A. Rich, R. C. Shepard, and S. T. Mosley Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232. [Abstract] [Full Text] [PDF]

				L. K. Mattison, H. Ezzeldin, M. Carpenter, A. Modak, M. R. Johnson, and R. B. Diasio Rapid Identification of Dihydropyrimidine Dehydrogenase Deficiency by Using a Novel 2-13C-Uracil Breath Test Clin. Cancer Res., April 15, 2004; 10(8): 2652 - 2658. [Abstract] [Full Text] [PDF]

				H. Ezzeldin, M. R. Johnson, Y. Okamoto, and R. Diasio Denaturing High Performance Liquid Chromatography Analysis of the DPYD Gene in Patients with Lethal 5-Fluorouracil Toxicity Clin. Cancer Res., August 1, 2003; 9(8): 3021 - 3028. [Abstract] [Full Text] [PDF]

				B. Keith, X.-D. Guo, S. Zentko, N. Harold, B. Schuler, M. Quinn, J. Shapiro, and J. L. Grem Impact of Two Weekly Schedules of Oral Eniluracil Given with Fluorouracil and Leucovorin on the Duration of Dihydropyrimidine Dehydrogenase Inhibition Clin. Cancer Res., May 1, 2002; 8(5): 1045 - 1050. [Abstract] [Full Text] [PDF]

				M. R. Johnson, K. Wang, and R. B. Diasio Profound Dihydropyrimidine Dehydrogenase Deficiency Resulting from a Novel Compound Heterozygote Genotype Clin. Cancer Res., March 1, 2002; 8(3): 768 - 774. [Abstract] [Full Text] [PDF]

				J. L. Grem, N. Harold, J. Shapiro, D.-Q. Bi, M. G. Quinn, S. Zentko, B. Keith, J. M. Hamilton, B. P. Monahan, S. Donavan, et al. Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors J. Clin. Oncol., December 1, 2000; 18(23): 3952 - 3963. [Abstract] [Full Text] [PDF]

				S. D. Baker, R. B. Diasio, S. O’Reilly, V. S. Lucas, S. P. Khor, S. E. Sartorius, R. C. Donehower, L. B. Grochow, T. Spector, J. A. Hohneker, et al. Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil J. Clin. Oncol., February 14, 2000; 18(4): 915 - 915. [Abstract] [Full Text] [PDF]

				M. R. Johnson, A. Hageboutros, K. Wang, L. High, J. B. Smith, and R. B. Diasio Life-Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-deficient Patient after Treatment with Topical 5-Fluorouracil Clin. Cancer Res., August 1, 1999; 5(8): 2006 - 2011. [Abstract] [Full Text] [PDF]